logo
logo
  • Technology
    • Patent
  • Clinical study
  • Investors
    • Investors Page
    • Shares
    • Second Quarter 2021
    • Words from CEO
    • Vision & Strategy
    • Market
    • Ownership
    • Financial Calendar
    • Financial reports
    • General Meetings
    • Emissions
    • IR Material
    • Certified Adviser
  • Press
    • Press releases
    • Presentations
    • The company in the media
  • Team
    • SpectraCure’s team
    • Corporate governance
    • Management
  • Contact
  • English
    • Svenska
  • Search
Diff i %:
0.96
Diff i SEK:
0.09
Köp:
9.46
Sälj:
9.51
Senaste:
9.51
Högst:
9.92
Lägst:
9.33
Antal:
123 218
Tid:
2021-09-24 17:29:43
  • Shares
  • Ownership
  • Financial Calendar
  • Financial reports
  • General Meetings
  • Emissions
  • IR Material
  • Certified Adviser
  • Investors Page
  • Second Quarter 2021
  • Words from CEO

5 - 23 June 2020

  • SpectraCure Prospect 2020
  • Warrant Terms
  • Application form without precedence
  • Special application form
  • Teaser

12-30 October 2018

  • Memorandum
  • Additional documentation
  • Subscription form
  • Teaser

2-16 December 2016

  • Memorandum
  • Subscription form
  • Teaser

25 May-12 June 2015

  • Memorandum
  • Subscription form
  • Teaser

PAGES

  • SpectraCure’s team
  • Clinical study
  • Investors
  • Contact with SpectraCure
  • Press
  • SpectraCure’s team

PRESS

  • Presentations
  • Press releases Archive
  • The company in the media
  • Presentations

INVESTORS

  • Shares
  • Ownership
  • Financial Calendar
  • Financial reports
  • General Meetings
  • Emissions
  • IR Material
  • Certified Adviser
  • Investors Page
  • Second Quarter 2021
  • Words from CEO

SPECTRACURE IN SHORT

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as “Interstitial Photodynamic Therapy”, PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region.

SOCIAL MEDIA

OUR POLICIES

Integritetspolicy
Arbetsmiljöpolicy
Cookie Information

© 2021 SpectraCure. All rights reserved

By continuing to use this website you consent to using cookies. For more information about cookies and how we use them, please see our Cookie information and Privacy Policy.

You can find out more about which cookies we are using or switch them off in settings.

Powered by  GDPR Cookie Compliance
Privacy Overview

SpectraCure uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Cookie Policy

More information about our Cookie Policy